Eli Lilly's weight-loss drug helps nearly 99% of patients remain diabetes-free
Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...
The Motley Fool19h
Did Viking Therapeutics Just Say "Checkmate" To Eli Lilly?
Right now, Eli Lilly dominates the weight loss industry thanks to its dual agonists Mounjaro and Zepbound. Viking ...
Hosted on MSN14h
Why Eli Lilly’s CEO says failing faster is essential to the company’s success
On this episode of Fortune’s Leadership Next podcast, host Diane Brady talks to Eli Lilly chair and CEO Dave Ricks. They ...
CNBC on MSN14d
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed
Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...
Yahoo Finance29d
Eli Lilly announces one-year histologic mirikizumab data
Eli Lilly announced data demonstrating more patients ... Week, held in Vienna, Austria from October 12-15. Mirikizumab is an IL23p19 antagonist that selectively binds to the p19 subunit of IL ...
Humanitarian Organization Criticizes Eli Lilly, Novo Nordisk And Sanofi Of Having 'Double Standards' For High Insulin Price
MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...
1 Stubborn Cloud and 2 Silver Linings for Eli Lilly Stock
Conditions are getting a bit more challenging for the drugmaker.
The Associated Press - Business News on MSN14d
Eli Lilly’s third quarter earnings miss and forecast cut lead to sharp stock drop
Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...
Investopedia16d
What You Need To Know Ahead of Eli Lilly's Earnings Wednesday
Paulo Nunes dos Santos / Bloomberg via Getty Images Eli Lilly will report third-quarter earnings Wednesday morning, with the focus remaining on the production and sales of its popular weight-loss ...
ABC News15d
Eli Lilly’s third quarter earnings miss and forecast cut lead to sharp stock drop
Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two key drugs that missed expectations INDIANAPOLIS -- Eli Lilly is dialing ...